Coldstream Capital Management Inc. Acquires 12,694 Shares of Medtronic PLC $MDT

Coldstream Capital Management Inc. increased its holdings in shares of Medtronic PLC (NYSE:MDT) by 24.2% during the 3rd quarter, Holdings Channel.com reports. The fund owned 65,151 shares of the medical technology company’s stock after acquiring an additional 12,694 shares during the period. Coldstream Capital Management Inc.’s holdings in Medtronic were worth $6,206,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in MDT. Brighton Jones LLC boosted its holdings in Medtronic by 1,368.0% during the fourth quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock valued at $3,194,000 after purchasing an additional 37,265 shares in the last quarter. Sivia Capital Partners LLC raised its holdings in shares of Medtronic by 9.6% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company’s stock worth $380,000 after buying an additional 381 shares in the last quarter. Frank Rimerman Advisors LLC raised its holdings in shares of Medtronic by 30.8% in the 2nd quarter. Frank Rimerman Advisors LLC now owns 9,541 shares of the medical technology company’s stock worth $832,000 after buying an additional 2,247 shares in the last quarter. Pinnacle Wealth Planning Services Inc. lifted its position in shares of Medtronic by 5.1% during the 2nd quarter. Pinnacle Wealth Planning Services Inc. now owns 4,453 shares of the medical technology company’s stock worth $388,000 after buying an additional 215 shares during the period. Finally, Empowered Funds LLC lifted its position in shares of Medtronic by 33.8% during the 2nd quarter. Empowered Funds LLC now owns 141,713 shares of the medical technology company’s stock worth $12,353,000 after buying an additional 35,790 shares during the period. Institutional investors and hedge funds own 82.06% of the company’s stock.

Insider Activity at Medtronic

In related news, EVP Harry Skip Kiil sold 52,524 shares of the firm’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total value of $5,132,120.04. Following the completion of the sale, the executive vice president owned 32,768 shares of the company’s stock, valued at $3,201,761.28. This trade represents a 61.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 0.26% of the stock is owned by company insiders.

Medtronic Stock Performance

Shares of NYSE:MDT opened at $87.17 on Thursday. The business has a fifty day moving average of $97.29 and a 200-day moving average of $96.78. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54. Medtronic PLC has a twelve month low of $79.55 and a twelve month high of $106.33. The firm has a market cap of $111.92 billion, a PE ratio of 24.28, a price-to-earnings-growth ratio of 2.27 and a beta of 0.71.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.34 by $0.02. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The business had revenue of $9.02 billion for the quarter, compared to the consensus estimate of $8.89 billion. During the same quarter in the prior year, the company earned $1.38 EPS. The firm’s quarterly revenue was up 5.8% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, equities research analysts predict that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, April 17th. Stockholders of record on Friday, March 27th will be given a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.3%. The ex-dividend date is Friday, March 27th. Medtronic’s dividend payout ratio is presently 79.11%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. UBS Group reaffirmed a “neutral” rating and issued a $104.00 target price on shares of Medtronic in a report on Wednesday, February 4th. Morgan Stanley lifted their price target on shares of Medtronic from $107.00 to $117.00 and gave the company an “overweight” rating in a report on Wednesday, November 19th. Wells Fargo & Company began coverage on shares of Medtronic in a research report on Friday, January 30th. They issued an “overweight” rating and a $114.00 price target on the stock. Sanford C. Bernstein upped their price objective on shares of Medtronic from $111.00 to $112.00 and gave the stock an “outperform” rating in a research note on Friday, January 9th. Finally, Leerink Partners reaffirmed an “outperform” rating and set a $119.00 price objective on shares of Medtronic in a report on Tuesday, March 10th. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $110.74.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).